Cannabis DependenceCANAANCT07160153
Cannabis Abstinence and Neurocognitive Assessment in Adolescence
An observational study of Cannabis Dependence and Harmful Use, run by University Hospital Pilsen at 1 site in Czechia.
Trial summary
Cannabis Abstinence and Neurocognitive Assessment in Adolescence Read more about this study
- Who is it for?
- Ages 15 to 18 years
- Conditions the study is for
- Cannabis Dependence, Harmful Use, Cognitive Assessment
- What is being tested?
- Neurocognitive assessment and Urine toxicological assessment
- How many people
- 29 participants
- Where
- 1 siteCzechia
- Study dates
- 3 Dec 2024to 31 Aug 2029
- How long will I take part?
- 2 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.
Who may be able to join
- Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.
Who cannot join
- psychiatric comorbidity - Dual diagnosis, including psychotic disorders, mood disorders, severe organic brain damage, or autism spectrum disorder, with the exception of compensated and stabilized anxiety disorder. Psychopharmacological treatment is permitted, except for antipsychotics prescribed for psychosis.
- somatic comorbidity - Severe endocrine disorders such as diabetes mellitus, thyroid dysfunction, or severe cardiovascular disease.
- Violation of abstinence between the first and second neuropsychological assessments, as well as severe decompensation of mental state requiring modification of established psychopharmacological treatment.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Czechia1 site, 1 recruiting
- Recruiting
University Hospital Pilsen
Pilsen, Czechia, 30100
Jiri Podlipny, MD, Ph.D., +420 377 103 209, podlipny@fnplzen.cz
Frantisek Nekvapil, MD, +420 377 103 101, nekvapilfr@fnplzen.cz
About this study
Cannabis Abstinence and Neurocognitive Assessment in Adolescence
Read the detailed description
Evaluate the development of cognitive functions following attainment of abstinence in a group of adolescents with cannabis dependence or harmful cannabis use. Abstinence is confirmed by toxicological testing.
- Conditions
- Cannabis Dependence, Harmful Use, Cognitive Assessment
- Being tested
- Neurocognitive assessment, Urine toxicological assessment
- Keywords
- Cannabis Dependence, Cannabis Use Disorder, Abstinence, Cognitive Function, Disorder; Abstinence; Cognitive Function; Neuropsychological
- Medical subject headings
- Marijuana Abuse
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Neurocognitive assessmentDiagnostic test
Neurocognitive battery:
TMT-Trail Making Test Auditory Verbal Learning Test Stroop Test Tower of London (ToL), Shallice version Continuous Performance Test-Identical Pairs
Other psychometrics:
The level of dependence is quantified using the CAST (Cannabis Abuse Screening Test)
Urine toxicological assessmentDiagnostic test
Urine toxicological assessment
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use. Receives: Diagnostic Test: Neurocognitive assessment; Diagnostic Test: Urine toxicological assessment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in performance TMT-B
Change in performance on the Trail Making Test - Part B (TMT-B) [Time Frame: after 8 weeks of abstinence from cannabis]
Measured: 8 weeks
Secondary outcomes (4)
Change in performance on AVLT
Change in performance on the Auditory Verbal Learning Test (AVLT) [Time Frame: after 8 weeks of abstinence]
Measured: 8 weeks
Change in performance on the Stroop Test
Change in performance on the Stroop Test [Time Frame: after 8 weeks of abstinence]
Measured: 8 weeks
Change in performance on the Tower of London
Change in performance on the Tower of London (Shallice version) [Time Frame: after 8 weeks of abstinence]
Measured: 8 weeks
Change in performance on CPT-IP
Change in performance on the Continuous Performance Test - Identical Pairs (CPT-IP) [Time Frame: after 8 weeks of abstinence]
Measured: 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2025
- Study start3 Dec 2024
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Aug 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cannabis DependenceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 29 participants (estimated)
- Target duration
- 2 Months
Sponsor and investigators
- Lead sponsor
- University Hospital Pilsen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07160153
- Sponsor's protocol ID
- CANAA
- Acronym
- CANAA
- Status last verified
- Oct 2026
- First submitted
- 27 Aug 2025
- Last updated
- 2 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Not decided yet because we are still recruiting and waiting for primary outcome.
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cannabis Abstinence and Neurocognitive Assessment in Adolescence
- ClinicalTrials.gov ID
- NCT07160153
- Acronym / sponsor ID
- CANAA / CANAA
- Conditions
- Cannabis Dependence, Harmful Use, Cognitive Assessment
- Keywords
- Cannabis Dependence, Cannabis Use Disorder, Abstinence, Cognitive Function, Disorder; Abstinence; Cognitive Function; Neuropsychological
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 29 participants (estimated)
- Lead sponsor
- University Hospital PilsenUniversity, hospital or other
- Study start
- 3 Dec 2024 (actual)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Aug 2029 (estimated)
- First posted
- 8 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cannabis Abstinence and Neurocognitive Assessment in Adolescence
Detailed description
Evaluate the development of cognitive functions following attainment of abstinence in a group of adolescents with cannabis dependence or harmful cannabis use. Abstinence is confirmed by toxicological testing.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 2 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Group 1 | – | Diagnostic Test: Neurocognitive assessment, Diagnostic Test: Urine toxicological assessmentAdolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use. |
Who may qualify
- Ages
- 15 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.
Key inclusion criteria (1 listed)
- Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.
Key exclusion criteria (3 listed)
- psychiatric comorbidity - Dual diagnosis, including psychotic disorders, mood disorders, severe organic brain damage, or autism spectrum disorder, with the exception of compensated and stabilized anxiety disorder. Psychopharmacological treatment is permitted, except for antipsychotics prescribed for psychosis.
- somatic comorbidity - Severe endocrine disorders such as diabetes mellitus, thyroid dysfunction, or severe cardiovascular disease.
- Violation of abstinence between the first and second neuropsychological assessments, as well as severe decompensation of mental state requiring modification of established psychopharmacological treatment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Neurocognitive assessmentNeurocognitive battery: TMT-Trail Making Test Auditory Verbal Learning Test Stroop Test Tower of London (ToL), Shallice version Continuous Performance Test-Identical Pairs Other psychometrics: The level of dependence is quantified using the CAST (Cannabis Abuse Screening Test) | Diagnostic test | Group 1 |
| Urine toxicological assessmentUrine toxicological assessment | Diagnostic test | Group 1 |
Primary outcome
Change in performance TMT-B
Time frame: 8 weeks
Change in performance on the Trail Making Test - Part B (TMT-B) [Time Frame: after 8 weeks of abstinence from cannabis]
4 secondary outcomes
Change in performance on AVLT
Time frame: 8 weeks
Change in performance on the Stroop Test
Time frame: 8 weeks
Change in performance on the Tower of London
Time frame: 8 weeks
Change in performance on CPT-IP
Time frame: 8 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2026.
- Individual participant dataSharing planned: Undecided. Not decided yet because we are still recruiting and waiting for primary outcome.
Related trials for Cannabis Dependence
Active, not recruitingPhase 1
Psilocybin-assisted Treatment for Cannabis Use Disorder
Cannabis Use Disorder
Recruiting
Young Adult Tobacco/Nicotine and Cannabis Co-use
Tobacco Use Disorder, Nicotine Dependence
Not yet recruiting
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
Asperger's Disorder, Asperger Disorder
Not yet recruitingEarly Phase 1
Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream
Cannabis Dependence
Not yet recruitingPhase 2
Trial of Tirzepatide for the Treatment of Cannabis Use Disorder
Cannabis Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cannabis Dependence and Harmful Use, run by University Hospital Pilsen at 1 site in Czechia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jiri Podlipny, MD, Ph.D. (+420 377 103 209, podlipny@fnplzen.cz), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in performance TMT-B (time frame: 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2026.